Dr. Basho on the Integration of Trastuzumab Deruxtecan in HER2+ Breast Cancer

Video

In Partnership With:

Reva K. Basho, MD, discusses the integration of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Reva K. Basho, MD, assistant professor of medicine, co-director, Women’s Cancer Program, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, discusses the integration of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive breast cancer.

Following its FDA approval in December 2019, trastuzumab deruxtecan has become a standard third- or fourth-line therapy for patients with HER2-positive breast cancer, Basho says. When to sequence the agent is largely dependent on patient and physician preferences, Basho adds.

However, toxicity remains a concern with trastuzumab deruxtecan, particularly with regard to the risk of fatal interstitial lung disease (ILD), Basho explains. Other therapies that are available for later-line use in HER2-positive breast cancer are generally well tolerated with limited alopecia, Basho says. As such, safety needs to be considered when selecting trastuzumab deruxtecan for a patient, Basho concludes.


Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD